<rdf:RDF xmlns:bam="http://www.elsevier.com/xml/schema/rdf/BasicAssetMetadata-1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:pav="http://purl.org/swan/pav/provenance/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:rgn="http://www.elsevier.com/xml/schema/rdf/LDR-Satellite/Regions-1/" xmlns:sat="http://www.elsevier.com/xml/schema/rdf/LDR-Satellites/Base-1/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:tag="http://www.elsevier.com/xml/schema/rdf/LDR-Satellites/TagAnnot-1/" xmlns:ecm="http://www.elsevier.com/xml/schema/rdf/common/Metadata-1/" xmlns:pmi="http://prismstandard.org/namespaces/pmi/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <sat:Satellite rdf:about="http://data.elsevier.com/metadata/BAM-1/pii:S2405844017326725">
      <sat:describesResource rdf:resource="http://vtw.elsevier.com/content/pii/S2405844017326725"/>
      <sat:describesResource rdf:resource="http://api.elsevier.com/content/article/DOI:10.1016/j.heliyon.2017.e00442"/>
      <sat:describesResource rdf:resource="http://api.elsevier.com/content/article/PII:S2405-8440(17)32672-5"/>
      <sat:satellite-type rdf:resource="http://data.elsevier.com/namespaces/LDR-Satellites/BasicAssetMetadata-1/"/>
      <sat:project rdf:resource="http://data.elsevier.com/enh-project/VTW"/>
      <pav:createdBy rdf:resource="http://data.elsevier.com/enh-service/LDR-VTW-INT"/>
      <pav:createdOn>2019-10-29T13:24:33Z</pav:createdOn>
    </sat:Satellite>
    <rdf:Description rdf:about="http://data.elsevier.com/metadata/BAM-1/pii:S2405844017326725">
      <dct:title>Research synergy and drug development: Bright stars in neighboring constellations</dct:title>
      <dct:isPartOf rdf:resource="http://vtw.elsevier.com/content/pii/S2405844016X00242"/>
      <bam:orderedCreatorList>
        <rdf:Seq>
          <rdf:li>Samet Keserci</rdf:li>
          <rdf:li>Eric Livingston</rdf:li>
          <rdf:li>Lingtian Wan</rdf:li>
          <rdf:li>Alexander R. Pico</rdf:li>
          <rdf:li>George Chacko</rdf:li>
        </rdf:Seq>
      </bam:orderedCreatorList>
      <dct:creator>Samet Keserci</dct:creator>
      <dct:creator>Eric Livingston</dct:creator>
      <dct:creator>Lingtian Wan</dct:creator>
      <dct:creator>Alexander R. Pico</dct:creator>
      <dct:creator>George Chacko</dct:creator>
      <dct:date>2017-11-15</dct:date>
      <dct:modified>2017-10-26T00:00:00Z</dct:modified>
      <dct:created>2017-09-16T00:00:00Z</dct:created>
      <dct:publisher>Elsevier Ltd</dct:publisher>
      <dct:language>en</dct:language>
      <dct:type rdf:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1.1"/>
      <dct:abstract>Abstract Drug discovery and subsequent availability of a new breakthrough therapeutic or ‘cure’ is a compelling example of societal benefit from research advances. These advances are invariably collaborative, involving the contributions of many scientists to a discovery network in which theory and experiment are built upon. To document and understand such scientific advances, data mining of public and commercial data sources coupled with network analysis can be used as a digital methodology to assemble and analyze component events in the history of a therapeutic. This methodology is extensible beyond the history of therapeutics and its use more generally supports (i) efficiency in exploring the scientific history of a research advance (ii) documenting and understanding collaboration (iii) portfolio analysis, planning and optimization (iv) communication of the societal value of research. Building upon prior art, we have conducted a case study of five anti-cancer therapeutics to identify the collaborations that resulted in the successful development of these therapeutics both within and across their respective networks. We have linked the work of over 235,000 authors in roughly 106,000 scientific publications that capture the research crucial for the development of these five therapeutics. Applying retrospective citation discovery, we have identified a core set of publications cited in the networks of all five therapeutics and additional intersections in combinations of networks. We have enriched the content of these networks by annotating them with information on research awards from the US National Institutes of Health (NIH). Lastly, we have mapped these awards to their cognate peer review panels, identifying another layer of collaborative scientific activity that influenced the research represented in these networks.</dct:abstract>
      <bam:year>2017</bam:year>
      <bam:subtype rdf:resource="http://data.elsevier.com/vocabulary/ElsevierPubItemTypes/FLA"/>
      <prism:copyright>The Authors</prism:copyright>
      <prism:publicationName>Heliyon</prism:publicationName>
      <prism:issn>2405-8440</prism:issn>
      <prism:aggregationType rdf:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1"/>
      <prism:coverDisplayDate>November 2017</prism:coverDisplayDate>
      <prism:volume>3</prism:volume>
      <prism:number>11</prism:number>
      <prism:keyword>Information science</prism:keyword>
      <prism:keyword>Cancer research</prism:keyword>
      <dct:description>Drug discovery and subsequent availability of a new breakthrough therapeutic or ‘cure’ is a compelling example of societal benefit from research advances. These advances are invariably collaborative, …</dct:description>
      <prism:channel rdf:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1.1.1"/>
      <ecm:identifier>pii:S2405844017326725</ecm:identifier>
      <dct:identifier>HELIYON_2017_2598</dct:identifier>
      <bam:formattedPII>S2405-8440(17)32672-5</bam:formattedPII>
      <prism:doi>10.1016/j.heliyon.2017.e00442</prism:doi>
      <bam:publicationTimeStart>2017-11-01T00:00:00Z</bam:publicationTimeStart>
      <bam:publicationTimeEnd>2017-11-30T23:59:59Z</bam:publicationTimeEnd>
    </rdf:Description>
  </rdf:RDF>